A STUDY OF SERUM MICRORNA-155: A POTENTIAL NOVEL BIOMARKER FOR CARDIOVASCULAR COMPLICATIONS IN EGYPTIAN PATIENTS WITH END-STAGE RENAL DISEASE

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Medical Biochemistry, Faculty of Medicine, University of Alexandria

2 Department of Medical Biochemistry, Faculty of Medicine, Alexandria University.

3 Department of Internal Medicine, Faculty of Medicine, University of Alexandria, Egypt

4 Department of Medical Biochemistry, Faculty of Medicine, Alexandria University

Abstract

End stage renal disease (ESRD)is a chronic kidney disease (CKD) characterized by a decreased glomerular filtration rate (GFR) of less than 15 mL/min. Hypertension and diabetes mellitus are the leading causes of ESRDin Egypt. Cardiovascular disease (CVD) is present in > 50% of patients undergoing dialysis and the relative risk of death due to CVD in haemodialysis(HD) patients is 20 times higher than in the general population. All of the available diagnostic tools for atherosclerotic CVD are less reliable in CKD patients in comparison with those without. Consequently, there is a crucialneed for specific CVD markers for all CKD patients. MicroRNAs (MiRs), which are defined as small non-coding RNA fragments with an average length of 19-25 nucleotides, are promising diagnostic tools in this field.The multifunctional miR-155 is involved inmultiple physiological processes and its dysregulation is associated with several pathologies including CKD and CVDs.
Aim of the work
The current study aimed to study the level of miR-155 in the peripheral bloodof ESRD Egyptian patients as a potential biomarker for adverse CV outcomes in these patients.

Keywords

ALEXMED ePosters
Volume 6, Issue 1
January 2024
Pages 11-12

Files

Share

How to cite

Statistics